Table 5.
Variables | PAS less than 50% (n = 46 eyes) | PAS more than 50% (n = 24 eyes) | ||||
---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | ||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Preoperative PRP (versus not done) | 0.34 (0.08–1.37) | 0.130 | 0.51 (0.12–2.13) | 0.354 | ||
Presence of NVA (versus absence) | 0.39 (0.08–1.90) | 0.242 | NA∗ | |||
IVB group (versus control) | 0.29 (0.08–1.10) | 0.069 | 1.19 (0.37–3.81) | 0.775 | ||
Number of IVB injection (per 1-time injection) | 0.39 (0.15–1.06) | 0.064 | 0.39 (0.15–1.06) | 0.064 | 0.91 (0.51–1.61) | 0.743 |
Baseline IOP (mmHg) | 1.05 (0.98–1.13) | 0.186 | 1.02 (0.95–1.09) | 0.624 | ||
Baseline BCVA (LogMAR) | 1.05 (0.89–1.88) | 0.881 | 1.25 (0.56–2.78) | 0.582 |
∗All 24 eyes had NVA. HR = hazard ratio; CI = confidence interval; NVA = neovascularization of angle; PAS = peripheral anterior synechiae; IVB = intravitreal bevacizumab; IOP = intraocular pressure; BCVA = best-corrected visual acuity; MAR = minimal angle of resolution; NA = nonapplicable. Variables with P < 0.10 in univariate analysis were entered into multivariate analysis. Multivariate model using a backward elimination approach based on likelihood ratio; variables were entered in the model if P < 0.05 and removed if P > 0.10 in the saturated multivariate model.